AbbVie to acquire Apogee Therapeutics for $10.9B; adds zumilokibart pipeline

AbbVie Inc.

Total equity value ~$10.9 billion, AbbVie to pay $135.11 per share in cash for all outstanding shares.
Apogee lead asset zumilokibart (APG777) is a half-life extended anti-IL-13 antibody for atopic dermatitis and asthma.
Transaction expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.
Deal projected to be accretive to AbbVie adjusted diluted EPS beginning 2032; key shareholders support.
AbbVie will host an investor conference call on June 22 at 8:00 a.m. CT to discuss the transaction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.